EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY 4.0

A multicenter evaluation of the Technoscreen ADAMTS13 activity semi‐quantitative screening test for thrombotic thrombocytopenic purpura diagnosis and exclusion

Jared Stephenson, Kent Chapman, Soma Mohammed, Diane Zebeljan, Monica Ahuja, Dea Donikian, Leonardo Pasalic iD, Penelope Motum, Danny Hsu iD, Timothy Brighton, Emmanuel J Favaloro iD

International Journal of Laboratory Hematology · 2023

DOI: 10.1111/ijlh.14077 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift International Journal of Laboratory Hematology, 2023. Verfasst von Jared Stephenson und 10 weiteren Autor:innen. Beteiligte Einrichtung: Haematology, NSW Health Pathology, Liverpool Hospital, New South Wales, Australia. Hauptthemen laut MEDLINE: Purpura, Thrombotic Thrombocytopenic, Anemia, Hemolytic, Vascular Diseases. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NSW Health Pathology.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Thrombotic thrombocytopenic purpura (TTP) is a rare but potentially fatal microangiopathy, with an untreated mortality rate of around 90%. TTP is caused by severe deficiency in ADAMTS13, which results in accumulation of ultra large von Willebrand factor multimers, triggering a consumptive thrombocytopenia, microangiopathic hemolytic anemia and end‐organ dysfunction and damage. Demonstration of severe ADAMTS13 deficiency is diagnostic for TTP, but long turnaround times for quantitative activity testing often necessitates empirical plasma exchange and/or caplacizumab treatment.

Methods

Multisite ( n = 4) assessment of the Technoscreen ADAMTS13 activity assay (semi‐quantitative flow through screening assay) for diagnosis/exclusion of TTP compared to current standard practice of quantitative assays (ELISA or chemiluminescence AcuStar).

Results

A total of 128 patient samples were analyzed, with quantitative ADAMTS13 values ranging from 0% to 150%. The Technoscreen assay demonstrated high sensitivity and negative predictive value (NPV) for ADAMTS13 deficiency, but low specificity and positive predictive value (PPV), especially with one lot of reagent. Good inter‐observer reliability was demonstrated. Excluding one possibly compromised batch and other test failures, results of 80 samples yielded sensitivity of 100% (95% CI = 84–100), specificity of 90% (80–95), PPV 77% (58–89) and NPV 100% (93–100).

Conclusion

The Technoscreen assay appears to be a reliable screening test for ADAMTS13 activity to exclude TTP in routine clinical practice. However, the assay falsely identified ADAMTS13 deficiency in many cases, partially batch related, which mandates confirmation with a quantitative assay, as well as initial assessment of kits as ‘fit for purpose’ prior to use for patient testing.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Purpura, Thrombotic ThrombocytopenicAnemia, HemolyticVascular DiseasesHumansReproducibility of ResultsPlasma ExchangeADAMTS13 Protein

Stichwörter der Autor:innen

ADAMTS13TTPTechnoscreenplasma exchangethrombotic thrombocytopenic purpura

Substanzen

ADAMTS13 ProteinADAMTS13 protein, human

Autor:innen und Institutionen

  • Haematology, NSW Health Pathology, Liverpool Hospital, New South Wales, Australia.
  • Haematology, NSW Health Pathology, John Hunter Hospital, Newcastle, New South Wales, Australia.
  • Haematology, Institute of Clinical Pathology and Medical Research (ICPMR), NSW Health Pathology, Westmead Hospital, Westmead, New South Wales, Australia.
  • Haematology, NSW Health Pathology, St George Hospital, New South Wales, Australia.
  • Haematology, NSW Health Pathology, Prince of Wales Hospital, Randwick, New South Wales, Australia.
  • Sydney Centres for Thrombosis and Haemostasis, Westmead, New South Wales, Australia.

ORCID-Profile: Leonardo Pasalic, Danny Hsu, Emmanuel J Favaloro

Förderung

  • NSW Health Pathology

Zitieren

APA

Stephenson, J., Chapman, K., Mohammed, S., Zebeljan, D., Ahuja, M., Donikian, D., Pasalic, L., Motum, P., Hsu, D., Brighton, T., & Favaloro, E. J. (2023). A multicenter evaluation of the Technoscreen ADAMTS13 activity semi‐quantitative screening test for thrombotic thrombocytopenic purpura diagnosis and exclusion. International Journal of Laboratory Hematology. https://doi.org/10.1111/ijlh.14077

Vancouver

Stephenson J, Chapman K, Mohammed S, Zebeljan D, Ahuja M, Donikian D, et al. A multicenter evaluation of the Technoscreen ADAMTS13 activity semi‐quantitative screening test for thrombotic thrombocytopenic purpura diagnosis and exclusion. International Journal of Laboratory Hematology. 2023. doi:10.1111/ijlh.14077

BibTeX
@article{Stephenson2023,
  author = {Stephenson, Jared and Chapman, Kent and Mohammed, Soma and Zebeljan, Diane and Ahuja, Monica and Donikian, Dea and Pasalic, Leonardo and Motum, Penelope and Hsu, Danny and Brighton, Timothy and Favaloro, Emmanuel J},
  title = {A multicenter evaluation of the Technoscreen ADAMTS13 activity semi‐quantitative screening test for thrombotic thrombocytopenic purpura diagnosis and exclusion},
  journal = {International Journal of Laboratory Hematology},
  year = {2023},
  doi = {10.1111/ijlh.14077}
}
Kostenlos starten →